A phase I-Ib/II, open-label, multi-center study of the safety and efficacy of MBG453 as single agent and in combination with PDR001 in adult patients with advanced malignancies

ovartis Pharma. K.K.0 个研究点目标入组 21 人开始时间: 2016年8月23日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1. Histologically documented advanced or metastatic solid tumors.
•2. Phase I-Ib part (including dose ranging part): Patients with advanced/metastatic solid tumors, with measurable or non-measurable disease as determined by RECIST v1.1, who have progressed despite standard therapy or are intolerant of standard therapy, or for whom no standard therapy exists.
•3. Phase II part (MBG453 single agent): Patients with advanced/metastatic solid tumors in the indication in which at least one confirmed PR or CR was seen during the dose escalation phase I part. Patients must have measurable disease as determined by RECIST v1.1, have progressed despite standard therapy or be intolerant to standard therapy.
•4. Phase II part (MBG453 in combination with PDR001): Patients with advanced/metastatic tumors in the below selected indications, with at least one measurable lesion as determined by RECIST v1.1, who have received standard therapy and are intolerant of standard therapy or have progressed following their last prior therapy:
•Melanoma (anti-PD-1/PD-L1 therapy naive or pre-treated)
•NSCLC (anti-PD-1/PD-L1 therapy naive or pre-treated)
•RCC (anti-PD-1/PD-L1 therapy naive or pre-treated)
•5. Must have a site of disease amenable to biopsy, and be a candidate for tumor biopsy according to the treating institution's guidelines. Patient must be willing to undergo a new tumor biopsy at screening/baseline, and during therapy on the study.

•1. Presence of symptomatic central nervous system (CNS) metastases.
•2. History of severe hypersensitivity reactions to any ingredient of study drugs and other monoclonal antibodies (mAbs) and/or their excipients.
•3. Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV) or Hepatitis C Virus (HCV) infection.
•4. Active autoimmune disease or a documented history of autoimmune disease, including ulcerative colitis and Crohn's disease or any condition that requires systemic steroids.
•5. Systemic steroid therapy or any immunosuppressive therapy (>=10mg/day prednisone or equivalent).
•6. Use of any vaccines against infectious diseases (e.g. varicella, pneumococcus) within 4 weeks of initiation of study treatment.
•7. Pre-treatment with anti-CTLA4 antibodies (Abs) in combination with any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathway.
•8. Participation in an interventional, investigational non-immunotherapy study within 2 weeks of the first dose of study treatment.
•9. Prior participation in an interventional, investigational cancer vaccine or immunotherapy study except for an anti-PD-1/PD-L1 study.

发起方

ovartis Pharma. K.K.